We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · March 10, 2020

Risk of Anxiety and Depression in Patients With Psoriasis Treated With Apremilast vs Biologics, DMARDs, and Corticosteroids

Journal of the European Academy of Dermatology and Venereology: JEADV


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of the European Academy of Dermatology and Venereology: JEADV
The Risk of Treated Anxiety and Treated Depression Among Patients With Psoriasis and Psoriatic Arthritis Treated With Apremilast Compared to Biologics, DMARDs and Corticosteroids: A Cohort Study in the United States MarketScan Database
J Eur Acad Dermatol Venereol 2020 Jan 25;[EPub Ahead of Print], C Vasilakis-Scaramozza, R Persson, KW Hagberg, S Jick

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading